Oncomed Pharmaceuticals Inc (NASDAQ:OMED) said it halted patient enrollment and dosing in all ongoing early-stage trials of two of its experimental cancer drugs over concerns of bone damage. Oncomed Pharmaceuticals Inc (NASDAQ:OMED) net profit margin is -97.60% and weekly performance is -4.90%. On last trading day company shares ended up $22.71. Analysts mean target price for the company is $44.20. Oncomed Pharmaceuticals Inc (NASDAQ:OMED) distance from 50-day simple moving average is -8.18%.
Zalicus Inc. (NASDAQ:ZLCS) Epirus Switzerland GmbH, a subsidiary of Boston-based Epirus Biopharmaceuticals focused on the global development and commercialization of biosimilar monoclonal antibodies, announced clinical data from a Phase 3 study of the efficacy and safety of BOW015, a biosimilar infliximab, in patients with active rheumatoid arthritis (RA). Zalicus Inc (NASDAQ:ZLCS) shares fell -13.91% in last trading session and ended the day on $1.30. ZLCS its return on assets is -98.20%. Zalicus Inc (NASDAQ:ZLCS) quarterly performance is 4.00%.
Aegis reaffirmed their buy rating on shares of CytRx (NASDAQ:CYTR) in a report released on Monday.CytRx Corporation (NASDAQ:CYTR) shares moved down -5.08% in last trading session and was closed at $5.04, while trading in range of $5.01-$5.46. CytRx Corporation (NASDAQ:CYTR) year to date performance is -19.62%.
The XOMA Corp (NASDAQ:XOMA) on May 7 announced its operational highlights and financial results for the first quarter ended March 31, 2014. The company recorded total revenues of $3.4 million for the three months ended March 31, 2014, compared with $9.5 million during the corresponding period of 2013, which included a $3.9 million milestone payment from SERVIER related to a product development program that XOMA subsequently transferred to Symplmed. XOMA Corp (NASDAQ:XOMA) ended the last trading day at $4.46. Company weekly volatility is calculated as 7.26% and price to cash ratio as 5.09. XOMA Corp (NASDAQ:XOMA) showed a negative weekly performance of -3.25%.
Equities researchers at Roth Capital started coverage on shares of Concert Pharmaceuticals (NASDAQ:CNCE) in a research report issued on Thursday. The firm set a “buy” rating and a $28.00 price target on the stock. Concert Pharmaceuticals Inc (NASDAQ:CNCE) net profit margin is -64.00% and weekly performance is 6.35%. On last trading day company shares ended up $8.87. Analysts mean target price for the company is $27.00. Concert Pharmaceuticals Inc (NASDAQ:CNCE) distance from 50-day simple moving average is -8.00%.
Leave a Reply